Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.5 (5'-nucleotidase)
 3,167 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An ultrastructural and ultracytochemical analysis of platelets was performed to assess the activity of 5'-AMPase and ATPase using a leukoconcentrate of the peripheral blood cells of non-pregnant women suffering from recurrent spontaneous abortion. The blood platelet populations were found to have increased proportions of light thrombocytes in phases I and II of the menstrual cycle, which was associated with pronounced ultrastructural and cytochemical signs of a release reaction showing their activated state: reduced density of the hyaloplasm, diminished quantity of specific and glycogen granules, development of the vacuolar system, 5'-AMPase and ATPase activity on the plasmalemma, light hyaloplasm, and in released specific granules and vacuoles. The release reaction is associated with a high contact activity of platelets which results in the formation of small and large platelet aggregates and attachment of other blood cells--erythrocytes, lymphocytes, and granulocytes. The intercellular fluid contains membrane fragments of destructive cells, including platelets with 5'-AMPase and ATPase activities, which may result in thromboplastin formation.
 ...
PMID:[An ultrastructural and ultracytochemical study of peripheral blood thrombocytes in women with habitual spontaneous abortion]. 216 70

Tissue thromboplastin injected i.v. in the form of microsomal fraction of the aorta intima was rapidly eliminated from the blood flow but did not enter into the lymph in any considerable amount. The disintegration products of the microsomal fraction of the aorta intima are released into the blood flow mostly within 5 days as revealed by the 5'-nucleotidase activity.
 ...
PMID:[Circulation of tissue thromboplastin in the blood]. 647 63

The activities of NTPDase (EC 3.6.1.5, apyrase, CD39) and 5'-nucleotidase (EC 3.1.3.5, CD73) enzymes were analyzed in platelets from breast cancer patients. Initially, patients were compared in terms of length (years) of tamoxifen use. The following groups were studied: breast cancer patients who did not use tamoxifen, patients using tamoxifen for 1-48 months, patients using tamoxifen for 49-84 months, and controls (healthy subjects). Results demonstrated that adenosine triphosphate (ATP) hydrolysis was enhanced (F(3,114)=8.53; P<0.001) and adenosine diphosphate (ADP) hydrolysis was reduced (F(3,106)=5.09, P=0.002) as a function of tamoxifen use, while adenosine monophosphate (AMP) hydrolysis was unchanged. Next, patients were compared statistically according to disease stage, determined by the tumor-node-metastasis (TNM) staging system for classifying breast tumor. ATP hydrolysis was significantly elevated in patients with stage I and II breast cancer (F(4,113)=4.35; P=0.003), but was normal in patients with stage III and IV cancer. ADP hydrolysis was reduced in stages II to IV (F(4,105)=3.88, P=0.006) and AMP hydrolysis was elevated in stage II (F(4,105)=3.45 P=0.01), but was normal in stages III and IV. Platelet aggregation time was similar in all patients regardless of tamoxifen use or disease stage. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were also within the normal range and similar among all groups. Similarly, fibrinogen and fibrin degradation product (FDP) were unchanged in all groups. In conclusion, our study demonstrated for the first time that hydrolysis of adenine nucleotides is modified in platelets from breast cancer patients taking tamoxifen.
 ...
PMID:Enzymes that hydrolyze adenine nucleotides in platelets from breast cancer patients. 1594 10